S1418/BR006 A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Triple Negative Breast Cancer
  • Age: Between 18 - 90 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1.  Patients must have histologically confirmed ER-, PR- and HER2-negative (triple-negative, TNBC) with residual invasive breast cancer (positive lymph nodes or at least 1 cm invasive cancer in the breast)


    2.  Patients must not have metastatic disease


    3.  Patients must have had neoadjuvant chemotherapy followed by surgery


    4.  Additional chemotherapy and/or radiation is allowed after surgery, but enrollment must occur shortly after


You may not be eligible for this study if the following are true:

  • 1.  Patients with a history of (non-infectious) pneumonitis that required steroid or evidence of active pneumonitis


    2.  Patients with certain autoimmune diseases


    3.  Patients who have had prior immunotherapy with anti-PD-L1, anti-PD-1, anti-CTLA4 or similar drugs

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.